Alpha Tau Medical (NASDAQ:DRTS) Upgraded to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Alpha Tau Medical (NASDAQ:DRTS – Get Rating) from a sell rating to a hold rating in a report published on Friday morning, Zacks.com reports.

According to Zacks, “Alpha Tau Medical Ltd. is a medical device company. It focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha Tau Medical Ltd., formerly known as Healthcare Capital Corp., is based in JERUSALEM. “

A number of other equities analysts have also recently weighed in on DRTS. Piper Sandler started coverage on shares of Alpha Tau Medical in a research note on Friday, April 8th. They set an overweight rating and a $19.00 price target on the stock. Cantor Fitzgerald began coverage on shares of Alpha Tau Medical in a research report on Thursday. They issued an overweight rating and a $20.00 price objective on the stock. Finally, Citigroup began coverage on shares of Alpha Tau Medical in a research report on Monday, April 4th. They issued a buy rating and a $21.00 price objective on the stock.

NASDAQ:DRTS opened at $9.47 on Friday. Alpha Tau Medical has a fifty-two week low of $8.27 and a fifty-two week high of $20.65.

Alpha Tau Medical Company Profile (Get Rating)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers.

Recommended Stories